ARTELO BIOSCIENCES INC (ARTL)

Company Profile

Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. The company is headquartered in Solana Beach, California and currently employs 5 full-time employees. The company went IPO on 2015-10-13. The company is focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system (ECS), a family of receptors and neurotransmitters that form a biochemical communication network throughout the body. The company is developing a dual cannabinoid agonist for the G protein-coupled receptor (GPCR) that targets a synthetic small molecule program, ART27.13, as a potential treatment for anorexia associated with cancer. Its second program ART26.12, is a small molecule lead product candidate from its platform of inhibitors of fatty acid binding proteins, notably Fatty Acid Binding Protein 5 (FABP5), which is undergoing pre-clinical research as a potential cancer therapeutic, for pain and inflammation, and in anxiety-related disorders, including post-traumatic stress disorder. In addition, the Company is also developing ART12.11 (CBD cocrystal), a solid-state composition of cannabidiol (CBD).

Company Info

ARTELO BIOSCIENCES INC

505 Lomas Santa Fe, Suite 160

Solana Beach CALIFORNIA 92037

P: 18589257049

CEO: Gregory D. Gorgas

Employees: 5

Website: https://artelobio.com/